Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucentis’ First Patients Mostly Taken From Macugen, Visudyne & Avastin – Genentech

This article was originally published in The Pink Sheet Daily

Executive Summary

The company recorded $153 mil. in sales for the macular degeneration product in its first full quarter on the market.

You may also be interested in...



NICE Recommends Lucentis In 20 Percent Of Wet AMD Patients

Draft guidance by U.K. watchdog recommends Lucentis in certain patients with wet AMD but does not recommend Macugen.

NICE Recommends Lucentis In 20 Percent Of Wet AMD Patients

Draft guidance by U.K. watchdog recommends Lucentis in certain patients with wet AMD but does not recommend Macugen.

Lucentis SAILOR Trial Hits Choppy Water

Interim analysis of neovascular AMD patients shows a higher incidence of stroke in patients treated with 0.5 mg dose of Lucentis.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel